Drug Delivery Systems Market

Drug Delivery Systems Market Outlook (2022 to 2032)

The worldwide drug delivery systems market was worth around US$ 40 Billion in 2022 and is expected to grow at a CAGR of more than 7.8% from 2022 to 2032, reaching roughly US$ 80 Billion by 2032. Demand for self-administration and home health care devices is expected to drive growth in the worldwide drug delivery systems market from 2022 to 2032.

Report Attributes	Details
Anticipated Base Year Value (2021)	US$ 38 Billion
Expected Market Value (2022)	US$ 40 Billion
Projected Forecast Value (2032)	US$ 80 Billion
Global Growth Rate (2022-2032)	7.8% CAGR
Growth Rate of the U.S (2022-2032)	7.2% CAGR
Expected Market Value of China (2032)	US$ 16 Billion
Key Drug Delivery Systems Service Providers	Boston Scientific Corporation; Johnson and Johnson Services, Inc.; Pfizer, Inc.; Baxter International, Inc.; Amgen, Inc.; Novartis AG; F. Hoffmann La-Roche Ltd; Bayer AG.

Continuous innovation in the global drug delivery systems market is allowing big and local producers to establish a diverse product range. Collaborations between leading market players for improved technical advances in drug delivery solutions are also expected to fuel the global drug delivery systems market during the projected period.

The medicine may be tailored to a specific spot using nanotechnology, making drugs more effective and reducing the possibility of adverse effects. Major market players are always conducting research and development in order to enhance their already extensive product offering.  Continuous expansion of drug delivery systems with high throughput, decreased waiting time, and enhanced result specificity is expected to boost the worldwide drug delivery systems market over the forecast period.

Drug Delivery Systems Market Revenue Analysis 2015 to 2021 vs. Future Outlook 2022 to 2032

During the projection period, the worldwide drug delivery systems market would rise at a robust CAGR of 7.8% (2022-2032). Over the last five decades, there has been an increase in the frequency of severe chronic and infectious illnesses, which has increased demand for medication development.

According to the WHO, nearly 70 million people have been infected with lethal illnesses such as HIV. Such developments have naturally encouraged healthcare providers to create better medications and delivery systems. The COVID-19 pandemic increased the viability of medication delivery systems. As the number of infections rises on a daily basis, hospitals and clinics are experiencing severe shortages of critical medical equipment such as respirators and ventilators.

Leading pharmaceutical and healthcare businesses have increased manufacture of critical drug delivery systems to overcome this shortfall. The relaxation of lockdowns and social distancing measures is predicted to significantly restore production cycles, resulting in higher output and resolving acute shortages of medication delivery devices and systems.

Prominent Drug Delivery Systems Industry Growth Drivers

Development of Innovative Medications and Biologics to Upscale the Market Growth

Progress in various biology-related activities has created an once-in-a-lifetime chance to better understand the molecular consequences of human illnesses and develop innovative medications and biologics based on these variables.

Lipid, protein, and polymer technologies with improved lipid distribution in the body, limiting drug degradation owing to the external environment, and lowering the pace of drug clearance are among the recently identified enhanced drug delivery methods. Because modern pharmaceuticals and biologics are more efficient with a lower dosage of medications, they must be supported by sophisticated drug delivery methods to get optimum efficacy from the drug.

Advanced Drug Delivery Technologies to Widen Drug Delivery Systems Deployment

Some of the controlled and targeted oral drug delivery systems are duocap (capsule-in-a-capsule), electro capsule, and light up delivery monitoring technology (LDMT), which give a novel means of manufacturing poorly soluble chemicals and monitoring medication release rate. Advanced drug delivery technologies are being developed in order to solve solubility issues and make medications more lipid-soluble.

As a result, they may readily penetrate lipid barriers in the body, avoiding external environment concerns like photo degradation and pH fluctuations from impacting the medicine and obtaining the optimal concentration at the desired site to deliver the best therapeutic benefit. As a result, these advancements are projected to boost market growth.

Key Challenges Prevalent in the Global Drug Delivery Systems Market

Expensive Treatments may Impede Growth Prospects

High treatment costs and a rise in medication recalls are expected to limit the worldwide drug delivery systems market throughout the forecast period from 2022 to 2032.

Country-wise Analysis

What is the Growth Outlook for Drug Delivery Systems in North America?

Increased Acceptance of Enhanced Drug Delivery Solutions widening Growth Opportunities

According to Fact.MR, North America held the largest share of the global drug delivery system market during the past years. This pattern is likely to continue throughout the projection period, with the company maintaining its market share while increasing at a CAGR of 7.2%. However, the surge in R&D costs for sophisticated medication delivery systems in the United States is a major source of worry among important stakeholders.

Key drivers for the North American drug delivery systems market are the growing preference for self-administration of pharmaceuticals, increasing advancements in injectable drug delivery systems, the high acceptance rate of new healthcare technologies, and the high incidence of chronic illnesses. Chronic illnesses and disorders are becoming more common. Heart disease is a primary cause of mortality, imposing a massive cost on individuals, communities, healthcare professionals, and systems.

Almost half of all individuals in the United States suffer from some form of cardiovascular disease. According to the American Cancer Society, approximately 2 million new instances of cancer are predicted to be identified in the United States in 2022, with 609,000 people expected to die from cancer. Greater incidence of chronic diseases, government attempts to raise awareness about such conditions, increased R&D operations, and the launch of improved drug delivery technologies will all help to boost the United States market during the forecast period.

How do Growth Prospects appear in the Chinese Market?

Increasing Cases of Acute Diseases such as TB and Pneumonia will drive Market Development in China.

The Chinese market will provide genuine growth prospects, expanding at a 7.1% CAGR throughout the projection period and accounting for more than one-fifth of the worldwide drug delivery systems market.

The prevalence of acute diseases such as TB and pneumonia in a country like China, as well as favorable reimbursement rules for major drug delivery manufacturers, will fuel market development in China.

Country-wise Forecast CAGRs in the Drug Delivery Systems Market

Country	Details
North America	7.2%
U.K	7%
China	7.1%
Japan	7%
South Korea	7.1%

Category-wise Insights

Why is Demand for Application Integration Rising Rapidly?

Targeted Drug Delivery Type to Snowball the Drug Delivery Systems Market

The targeted drug delivery type is predicted to be the dominating category, accounting for almost half of the worldwide drug delivery systems market and rising at a 6.8% CAGR during the forecast period. Nanotechnology application is a significant growth determinant for the segment. The incorporation of nanoparticles improves the penetration of the targeted tissue. These particles are easily absorbed by cells, allowing for more effective medication delivery. Microneedle medication administration is another prominent method.

The polymeric drug delivery market is expected to be the second-most profitable, growing at a CAGR of 7.3% during the projection period. The prominence of this delivery method can be ascribed to its effectiveness in large-scale localized medication distribution. Polymeric drug delivery is particularly beneficial in the treatment of chronic illnesses such as cancer, particularly solid tumors. It also has a reduced level of toxicity. During the projection period, the polymeric drug delivery segment will account for more than one-third of the worldwide drug delivery systems market.

Which Application will Leverage Drug Delivery Systems the Most?

Oncology Segment to be the Most Lucrative for Drug Delivery Systems Market

In terms of application, the oncology category will grow the quickest, with a CAGR of 7.5% accounting for more than a quarter of the market. The CNS category is the second-most profitable, accounting for more than one-fifth of the worldwide drug delivery systems market and rising at a 6.9% annual pace.

The rising frequency of malignancies such as leukemia, brain tumors, colon cancer, stomach cancer, and others has increased demand for sophisticated drug delivery systems in the oncology market. The CNS segment is predicted to grow due to an increase in demand for sophisticated treatment for a variety of neurological conditions such as dementia, epilepsy, and neuro infections.

Competitive Landscape

The present worldwide drug delivery systems market is extremely competitive, owing to the existence of several local and global drug delivery product producers. Extensive research activities and technical developments characterize the industry. The intensive competition among market participants is characterized by investment in R&D to produce new grade medication delivery products and solve issues, concerns, and side-effects of their use.

• In February 2020, Novartis AG received a patent for the invention of thermogelling peptide delivery systems that are administered as fluid sol at ambient temperature through an injection. The business also makes ZYKADIA, which is used to treat non-small cell lung cancer.
• Binocrit, a medication used to treat symptomatic anaemia associated with chronic renal failure in both adults and children, is also manufactured by the business. Another major market competitor, Pfizer, Inc., offers the iSecure, ABBOJECT, and CARPUJECT syringe systems. It also provides IV medication delivery devices, such as the ADD-Vantage ADDaptor delivery system.

Key Segments Covered in the Drug Delivery Systems Industry Report

• Drug Delivery Systems by Delivery System :

  • Intra Uterine Implants
  • Pro-drug Implants
  • Polymeric Drug Delivery
  • Targeted Drug Delivery

• Drug Delivery Systems by Route of Administration :

  • Oral
  • Injectable
  • Inhalation
  • Transdermal
  • Ocular
  • Nasal
  • Topical

• Drug Delivery Systems by Application :

  • Infectious Disease
  • Oncology
  • Ophthalmology
  • Urology
  • Diabetes
  • CNS
  • Others

• Drug Delivery Systems by Region :

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa (MEA)